临近年终，本是家家户户盘算一年收成、准备安心过年的时节，一则行业巨头暴雷的消息却让无数家庭 陷入恐慌。 一家年营收超500亿的中国500强黄金企业，旗下黄金理财项目集中逾期，更让人揪心的是，企业总部早 已人去楼空，只剩空荡荡的办公室和物业张贴的租赁终止告示。 小李留意到，这场暴雷波及了全国多个省份的普通百姓，不少人把一辈子的血汗钱、养老钱都投了进 去。 这些百姓的血汗钱还能追回来吗？这场看似突如其来的暴雷，背后是否藏着早已设计好的套路？ 被套路的普通百姓 在这场暴雷事件中，没有所谓的"大鳄"，全是一个个普通家庭的心酸与绝望。 有位投资者为了这份所谓的"稳健收益"，甚至把家里的好几套房子都抵押了，前后投进去700多万，如 今这些钱全都打了水漂，一家人的生活瞬间陷入绝境。 他当初之所以敢如此投入，就是因为相信这家企业的500强身份，觉得像金雅福这样的大公司肯定靠 谱，没成想最后却落得这般下场。 不只是大额投资者，不少小额投资者也没能幸免。 有位阿姨把自己30万的养老钱投了进去，原本想着到期后能多赚点钱补贴家用，没料到还没等到到期 日，就传来了理财逾期的消息。 省吃俭用攒了一辈子的积蓄，当初也是觉得这家企业靠谱，才 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 【文/羽扇观金工作室】 12月1日，武汉当代科技产业集团股份有限公司在中国银行间市场交易商协会发布公告称，公司于11月 28日收到中国证监会《立案告知书》（编号：证监立案字0052025019号），因涉嫌信息披露违法违规、 违规融资等，中国证监会决定对公司进行立案。在立案调查期间，公司将积极配合中国证监会的调查工 作，同时严格按照监管要求及相关规则的要求，及时履行后续进展情况的信息披露义务。 此前，11月29日，风证券股份有限公司发布公告，公司于2025年11月28日收到中国证券监督管理委员会 下发的《立案告知书》（编号：证监立案字【0052025018】号）。因涉嫌信息披露违法违规、违法提供 融资，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对 公司立案。 上述两案的证监立案字只差一号。分析人士指出，此次立案或与公司2022年年度报告中披露的原大股 东"当代系"资金占用事项有关。 天风证券2022年年度报告中披露，公司原直接和间接持股合计5%以上股份的股东武汉当代科技产业集 团股份有限公司通过第三方主体占用公司资金，截至 ...

Group 1 - Contemporary Group has been placed under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure and illegal financing [1][2] - The company was founded in July 1988 and is registered in Wuhan with a registered capital of 5.5 billion yuan, expanding into various sectors including pharmaceuticals, consumer goods, and culture [2] - The company has faced multiple bond defaults since April 2022, leading to a restructuring application filed by creditors in September 2024 due to its inability to repay debts [2] Group 2 - The former CSRC official, Guo Xudong, who was involved in the regulatory process, has been implicated in serious misconduct and later joined Contemporary Group as vice chairman [3]

Core Viewpoint - Yuwang Bio is facing significant financial challenges, including a 74% drop in net profit and high debt levels, while also engaging in controversial dividend practices that may jeopardize future shareholder interests [1][6][9]. Financial Performance - Yuwang Bio reported revenues of 5.34 billion, 6.61 billion, 8.32 billion, and 3.43 billion for the years 2022 to 2025 H1, with net profits of 0.67 billion, 1.02 billion, 1.25 billion, and 0.23 billion respectively, indicating a 27.13% decline in revenue and a 74.01% decline in net profit for 2025 H1 compared to the previous year [3][5]. - The company's gross profit margins decreased from 25.4% in 2022 to 20.7% in 2025 H1, contributing to the decline in net profit [3][5]. Market Position - Yuwang Bio is the largest supplier of food-grade refined fish oil globally, holding an 8.1% market share as of 2024 [3][5]. - The global market for food-grade fish oil has experienced a compound annual growth rate (CAGR) of -6.76% from 2020 to 2024, with a projected CAGR of 6.65% from 2025 to 2029, indicating limited growth potential [5]. Debt and Dividend Practices - The company's debt-to-asset ratio was over 90% in 2024 and remained above 83% in 2025 H1, while it declared a controversial dividend of 3.2 billion, exceeding its net profit for the three years from 2022 to 2024 [1][6][9]. - The 3.2 billion dividend was characterized as a "clearance dividend," which is defined as exceeding 80% of net profit over three years, raising concerns about the impact on future shareholder interests [8][9]. Internal Control Issues - Yuwang Bio reported a total of 1.59 billion in illegal bill financing and 2.42 billion in misallocated loan funds, totaling over 4 billion, indicating significant internal control failures [2][10][12]. - The company attributed these violations to a lack of familiarity with regulatory requirements, placing blame on the financial manager, which raises questions about overall governance and internal controls [12][13].

Core Viewpoint - Yuwang Bio Nutrition Co., Ltd. has submitted its IPO prospectus in Hong Kong, revealing significant financial challenges, including a 74% drop in net profit and a high debt ratio, raising concerns about its future profitability and governance practices [1][3][12]. Financial Performance - Yuwang Bio is the largest supplier of food-grade refined fish oil globally, with a market share of 8.1% as of 2024 [3]. - The company's revenue and net profit for the years 2022 to 2025 are as follows: - 2022: Revenue of 534 million RMB, Net Profit of 67 million RMB - 2023: Revenue of 661 million RMB, Net Profit of 102 million RMB - 2024: Revenue of 832 million RMB, Net Profit of 125 million RMB - 2025 (H1): Revenue of 343 million RMB, Net Profit of 23 million RMB - The company experienced a year-on-year revenue decline of 27.13% and a net profit decline of 74.01% in the first half of 2025 [3][5]. Profitability and Margin Issues - The gross profit margin has decreased from 25.4% in 2022 to 20.7% in the first half of 2025, contributing to the decline in net profit [3][5]. - The average selling prices of several core products have significantly dropped: - High-purity fish oil: from 323 thousand RMB/ton to 133 thousand RMB/ton (58.82% decrease) - Medium-purity fish oil: from 158 thousand RMB/ton to 74 thousand RMB/ton (53.16% decrease) - Low-purity fish oil: from 78 thousand RMB/ton to 45 thousand RMB/ton (42.31% decrease) - Fish oil soft capsules: from 155 thousand RMB/ton to 99 thousand RMB/ton (36.13% decrease) [5]. Debt and Dividend Practices - The company's debt ratio was over 90% in 2024 and remained above 83% in the first half of 2025 [7][8]. - Yuwang Bio declared a "clearing dividend" of 320 million RMB, which exceeds the total net profit of 294 million RMB for the years 2022 to 2024, raising concerns about the impact on future shareholder interests [10][11]. Internal Control and Compliance Issues - The company reported a total of 1.59 billion RMB in illegal bill financing and 2.42 billion RMB in misused loan funds, totaling over 4 billion RMB in compliance issues [2][12]. - Yuwang Bio attributed these violations to a lack of understanding of regulatory requirements, which raises questions about its internal governance and control mechanisms [15].